論文・技術情報追加のお知らせ

1. Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study.

長期作用型GnRHaの副作用解析、安全性プロフィールに差

対象DB：FAERS

2. Primary Suspect Drugs of Cataracts in Pediatric Patients: An FDA Adverse Events Reporting Database Analysis.

小児白内障関連薬をFAERS解析、3つの薬剤で安全性懸念

対象DB：FAERS

3. Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).

リプレチニブとスニチニブの副作用解析、安全性向上に寄与

対象DB：FAERS

4. Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system.

小児聴覚障害リスク薬剤調査、半数が警告未記載

対象DB：FAERS

5. Predicting Drug-Side Effect Relationships From Parametric Knowledge Embedded in Biomedical BERT Models: Methodological Study With a Natural Language Processing Approach.

BERTを活用し薬剤副作用関係予測、実用性示唆

対象DB：FAERS,KAERS

6. A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.

真性多血症治療薬、皮膚障害や感染症等の副作用に注意必要

対象DB：FAERS

7. Exploring Clinical Studies and the FDA Adverse Event Reporting System (FAERS) Database for nirogacestat-related Adverse Events.

ニロガセスタット、非重篤な副作用多発も卵巣毒性や視覚異常注意必要

対象DB：FAERS

8. Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world database.

モガムリズマブで免疫関連有害事象確認、心筋炎や肝炎など注意必要

対象DB：FAERS,VigiBase

9. Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database.

アジスロマイシン、年齢別リスク多様。高齢者で心血管問題顕著、適正使用要

対象DB：FAERS

10. Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T窶ｯcell engagers in multip myeloma.

BiTE療法で心血管有害事象リスク増、早期管理が重要

対象DB：FAERS

11. A Justification to Using the FDA Adverse Event Reporting System for Hypothesis Generation Regarding Benzoyl Peroxide.

FDA有害事象報告システムは過酸化ベンゾイル研究仮説の重要なツール

対象DB：FAERS

12. Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database.

スタチン誘発肝障害リスク高、フルバスタチン最大、監視必要

対象DB：FAERS

13. Tirzepatide Safety in Type 2 Diabetes: A Disproportionality Analysis of Adverse Events Using the FDA FAERS Database.

ティルゼパチドで既知の消化器リスク確認、新たな安全懸念も

対象DB：FAERS

14. Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS/TEN: A FAERS-Based Analysis.

免疫阻害剤がSJS/TENリスク増加、発症遅延確認

対象DB：FAERS

15. Comprehensive safety analysis of adverse events associated with eptinezumab in migraine treatment.

エプチネズマブで強い偏頭痛信号と稀な重篤副作用確認、追加研究必要

対象DB：FAERS

16. Post-marketing safety signals of imatinib: pharmacovigilance insights from the FDA Adverse Event Reporting System (FAERS) and implications for clinical practice.

イマチニブで予期された消化器症状と新規副作用確認、継続的監視が必要

対象DB：FAERS

17. Apixaban- and Rivaroxaban-Associated Bleeding: A Retrospective Analysis Using the FDA Adverse Event Reporting System.

リバーロキサバンで多臓器出血リスク増、アピキサバンが安全選択肢か

対象DB：FAERS

18. Assessing post-marketing safety of PDE5Is in erectile dysfunction: real-world evidence from the FDA adverse event reporting system.

PDE5Iで神経・心血管・眼系副作用確認、個別管理が重要

対象DB：FAERS

19. Safety profile of ramelteon from the perspective of physicians and pharmacists: a 20-year real-world pharmacovigilance analysis based on the FAERS database.

ラメルテオンで多様な副作用確認、個別治療と監視が重要

対象DB：FAERS

20. Cardiovascular safety of propranolol oral solution in infantile hemangiomas: a disproportionality analysis based on the FAERS database.

プロプラノロール液で末梢冷感・チアノーゼ確認、重篤心血管事象なし

対象DB：FAERS

21. Mifepristone-related foetal cardiac adverse events: findings from the postmarketing safety reports.

ミフェプリストンで胎児心リズム異常のリスク、構造異常は確認されず

対象DB：FAERS

22. HER2-targeted agents and interstitial lung disease: A real-world pharmacovigilance analysis using FAERS data.

HER2標的薬とILDの関連を確認、高齢者やT-Dxdで致死リスク増

対象DB：FAERS

23. Real-World safety profile of Fenfluramine in refractory epilepsy: a pharmacovigilance study based on FAERS database.

肺・三尖弁疾患や精神症状に注意が必要

対象DB：FAERS

24. Comprehensive Cardiovascular Risk Profiling in People Living with HIV: Insights from the Japanese Adverse Drug Event Report Database.

高齢者や糖尿病患者のHIV治療でABC含むARTが心血管リスク増加示唆

対象DB：JADER

25. Safety of Proton Pump Inhibitor in Paediatrics: A Study Based on EudraVigilance Data.

小児PPI使用で消化器障害が主要な副作用

対象DB：EudraVigilance

26. A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.

ケタミンとエスケタミンは自殺関連パラメータで増減混在

対象DB：VigiBase

27. Temporal Changes in Reporting of Neurodevelopmental Outcomes After Maternal Exposure to Valproate: A Contribution of the ConcePTION Project.

バルプロ酸妊娠使用後の報告増加、出版物や規制が認識向上に影響

対象DB：VigiBase

28. Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.

GLP-1 RAs使用、精神的副作用注意喚起

対象DB：VigiBase

29. Regional Disparities in Atrial Fibrillation Catheter Ablation Based on the Japanese National Survey.

AF治療率に地域差、社会経済要因と専門医数が影響

対象DB：DPC

30. High risk of postoperative complications in dialysis patients undergoing total hip arthroplasty: a database study of Japanese nationwide medical claims.

透析患者のTHA後、脱臼や再手術リスク増加

対象DB：DPC

31. Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance.

国際試験で人種・民族分類に課題、改善には多関係者の協力が必要

対象DB：JMDC

32. Changes in proportions of Cesarean section before and during the COVID-19 pandemic in Japan.

COVID-19流行時、日本の帝王切開率0.92%増、感染対策影響か

対象DB：NDB

33. Prompt versus Delayed Triple Therapy in COPD: Solutions to Time-Related Biases in Observational Studies.

COPD急性増悪後早期治療効果限定的、従来研究に時間的バイアス影響

対象DB：CPRD

34. Association between weight loss and reproductive outcomes among women with overweight or obesity: a cohort study using UK real-world data.

体重減少で妊娠率向上、妊娠糖尿病・帝王切開リスク軽減

対象DB：CPRD

35. Antibiotics for acute otitis media in children.

抗生物質は2歳未満重症例に効果、軽症は観察推奨

対象DB：CVAR